InskoBee: "APUS Draws Intense Global Investor Interest Amid Series of Merger and Investment Proposals"

Apimes, the bio subsidiary of InskoBee that was listed on the New York Stock Exchange (NYSE) in the United States this year, announced on October 21 that its U.S. subsidiary (APUS) is attracting strong interest from global investors.

Recently, APUS reportedly received merger and investment proposals from multiple global institutions, including major overseas investment and advisory firms. InskoBee is currently reviewing each proposal in detail and is carefully selecting a partner that can ensure both long-term growth potential and stability in clinical development.

The proposals are said to include a variety of collaboration options, such as: ▲ a merger and joint research in oncology clinical projects; ▲ large-scale funding for Phase 3 clinical trials through strategic investments in the form of structured equity in the United States; and ▲ mergers with companies holding cash-equivalent assets. Industry insiders assess that these proposals will not only accelerate APUS's global clinical development but also positively impact its market entry strategy after commercialization.

APUS is currently conducting a Phase 3 FDA clinical trial for severe osteoarthritis (OA). In particular, APUS's core technology platform is based on a differentiated mechanism that maximizes drug efficacy while minimizing side effects, and is regarded as having the potential to usher in a new era in the next-generation immunological disease therapeutics market.

The company is focusing on the possibility that these investment negotiations could lead not only to simple funding, but also to the expansion of its global research network and opportunities for technology transfer (license-out). It also analyzed that its credibility as a locally listed U.S. company and its transparent corporate governance have attracted the attention of global institutional investors.

An InskoBee representative stated, "We are carefully reviewing the most suitable investment partners at present, and if a collaboration is achieved, it will greatly support the advancement of our Phase 3 clinical trial for multiple sclerosis (MS) and enhance our corporate value," adding, "We will continue our research and development and attract further investment to ensure that the domestic bio industry is recognized on the global stage."

This content was produced with the assistance of AI translation services.